Scarica l'app Stockscreener
6.20
3.51%
0.21
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CAMP Giù?
Forum
Previsione
Frazionamento azionario
Camp 4 Therapeutics Corp Borsa (CAMP) Ultime notizie
CAMP4 to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Insilico’s big gain after Hong Kong listing: Finance Report - BioCentury
Sanofi adds HBV vaccine, shingles candidate via Dynavax takeout: Deals Report - BioCentury
Camp4 Therapeutics signs new Watertown lease, accelerates Cambridge exit By Investing.com - Investing.com Australia
Camp4 Therapeutics signs new Watertown lease, accelerates Cambridge exit - Investing.com
CAMP4 Therapeutics Restructures Leases and Expands Facilities - TipRanks
Deal Watch: Boehringer Signs On For Rectify’s Chronic Kidney Disease Assets - Citeline News & Insights
Is Camp4 Therapeutics Corporation a good long term investmentMarket Timing Techniques & Superior Capital Trading - earlytimes.in
Will Camp4 Therapeutics Corporation stock benefit from green energy trends2025 Technical Overview & Real-Time Buy Signal Notifications - Улправда
How Camp4 Therapeutics Corporation stock valuations compare to rivals2025 Sector Review & Real-Time Volume Triggers - Улправда
Market Rankings: How Camp4 Therapeutics Corporation stock performs in rate cut cyclesWeekly Trade Recap & Community Trade Idea Sharing - Улправда
Will Camp4 Therapeutics Corporation stock deliver better than expected guidanceTrade Entry Report & Long-Term Safe Investment Ideas - Улправда
GSK Deal Is Key Validation For CAMP4's Drug Discovery Platform: Analyst - Benzinga
Quarterly Recap: Will Camp4 Therapeutics Corporation stock outperform international peersJuly 2025 Chart Watch & Detailed Earnings Play Alerts - Улправда
CAMP4 Therapeutics: GSK Collaboration and Strengthened Funding Base De-Risk CMP-002 Development and Support Buy Rating - TipRanks
How Camp4 Therapeutics Corporation stock performs in rate cut cyclesJuly 2025 Update & Weekly High Momentum Picks - Улправда
CAMP4 Therapeutics (Nasdaq:CAMP) Enters Research and License Agreement with GSK - Kalkine Media
CAMP4 Therapeutics Announces $28 Million Common Stock Offering - TipRanks
CAMP4 Therapeutics (CAMP) to raise about $28M in 5M-share equity deal - Stock Titan
Will Camp4 Therapeutics Corporation stock outperform international peersGap Down & Advanced Technical Analysis Signals - Улправда
CAMP4 Therapeutics and GSK partner on ASO development for diseases By Investing.com - Investing.com Nigeria
CAMP4 Therapeutics prices $30 million common stock offering By Investing.com - Investing.com Nigeria
Camp4 Therapeutics shares slide after $30 million equity offering priced - MSN
CAMP4 and GSK enter strategic collaboration to advance RNA-based therapeutic discoveries - PharmaLive
CAMP4, GSK form RNA therapeutics collaboration agreement - TipRanks
CAMP4 Therapeutics prices $30 million common stock offering - Investing.com India
CAMP4 Announces Pricing of $30.0 Million Underwritten Offering of Common Stock - The Manila Times
CAMP4 Therapeutics and GSK partner on ASO development for diseases - Investing.com
Biotech offering to raise $30M for RNA drugs on genetic diseases - Stock Titan
CAMP4 and GSK Enter Strategic Collaboration to Advance RNA-Based Therapeutic Discoveries - The Manila Times
CAMP4 Therapeutics (NASDAQ: CAMP) inks GSK ASO deal with $17.5M upfront, up to $440M milestones - Stock Titan
Camp4 Therapeutics stock falls after pricing $30 million share offering - Investing.com
CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sahm
Cantor Fitzgerald reiterates Overweight rating on CAMP4 Therapeutics stock By Investing.com - Investing.com Australia
CAMP4 Therapeutics Corporation (CAMP) Slides 6% in Pre-market: Without a Fresh Catalyst - Stocks Telegraph
Cantor Fitzgerald reiterates Overweight rating on CAMP4 Therapeutics stock - Investing.com India
Following a 46% Decline Over Last Year, Recent Gains May Please Camp4 Therapeutics Corporation (NASDAQ:CAMP) Institutional Owners - 富途牛牛
After losing 46% in the past year, Camp4 Therapeutics Corporation (NASDAQ:CAMP) institutional owners must be relieved by the recent gain - simplywall.st
Positive week for Camp4 Therapeutics Corporation (NASDAQ:CAMP) institutional investors who lost 46% over the past year - Yahoo Finance
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Camp4 Therapeutics (CAMP) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
CAMP4 Therapeutics Corporation (CAMP) -6.6% in After-hours: Without a Clear Catalyst - Stocks Telegraph
Activity Recap: How Camp4 Therapeutics Corporation stock valuations compare to rivalsQuarterly Growth Report & Free Daily Entry Point Trade Alerts - BỘ NỘI VỤ
[424B3] Camp4 Therapeutics Corp Prospectus Filed Pursuant to Rule 424(b)(3) - Stock Titan
How Camp4 Therapeutics Corporation stock performs in interest rate cyclesEntry Point & Safe Entry Zone Tips - newser.com
Will Camp4 Therapeutics Corporation stock split again soonQuarterly Portfolio Report & Long-Term Investment Growth Plans - newser.com
Chart based exit strategy for Camp4 Therapeutics CorporationQuarterly Market Review & Precise Trade Entry Recommendations - newser.com
Best data tools to analyze Camp4 Therapeutics Corporation stock2025 Technical Overview & Reliable Breakout Forecasts - newser.com
28.63%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):